ImageneBio, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-25

Reporting Person: Renaud Ronald C JR (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.94	2028-05-09	Common Stock (54006)		Direct
Stock Option (Right to Buy)	$4.15	2029-03-19	Common Stock (71987)		Direct
Stock Option (Right to Buy)	$7.87	2031-03-01	Common Stock (97847)		Direct

Footnotes

F1: 25% of this option vested and became exercisable on March 7, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F2: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F3: 25% of this option shall vest and become exercisable on March 1, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.